Andrew Schally received his training in England, Canada, Sweden and USA. In the years 1954-1977 he worked in the field of neuroendocrinology. Dr. Schally’s group was responsible for the isolation and elucidation of the structure of hypothalamic LHRH. Dr. Schally was awarded the Nobel Prize in Physiology or Medicine in 1977 for his pioneer work on hypothalamic peptides. Grasping the therapeutic potential of hypothalamic hormones Dr. Schally switched to cancer research and he became an endocrine oncologist. He is a world leader on targeting hormone-related cancers and is largely responsible for the field of hormone ablation for the treatment of prostate and other cancers. Various classes of anticancer peptides including targeted to analogs peptide receptors on tumors were developed in his laboratory and are in clinical trials. Dr. Schally is the Distinguished Leonard M. Miller Professor of Pathology and Professor in the division of Hematology/Oncology of the Department of Medicine at the University of Miami Miller School of Medicine, Dr. Schally is also Chief of the Endocrine, Polypeptide Cancer Institute at the Veterans Affairs Medical Center, Miami, Florida and Distinguished Medical Research Scientist, US Department of Veterans Affairs. He has more than 2400 publications to his credit.

Andrew Schally received his training in England, Canada, Sweden and USA. In the years 1954-1977 he worked in the field of neuroendocrinology. Dr. Schally’s group was responsible for the isolation and elucidation of the structure of hypothalamic LHRH. Dr. Schally was awarded the Nobel Prize in Physiology or Medicine in 1977 for his pioneer work on hypothalamic peptides. Grasping the therapeutic potential of hypothalamic hormones Dr. Schally switched to cancer research and he became an endocrine oncologist. He is a world leader on targeting hormone-related cancers and is largely responsible for the field of hormone ablation for the treatment of prostate and other cancers. Various classes of anticancer peptides including targeted to analogs peptide receptors on tumors were developed in his laboratory and are in clinical trials. Dr. Schally is the Distinguished Leonard M. Miller Professor of Pathology and Professor in the division of Hematology/Oncology of the Department of Medicine at the University of Miami Miller School of Medicine, Dr. Schally is also Chief of the Endocrine, Polypeptide Cancer Institute at the Veterans Affairs Medical Center, Miami, Florida and Distinguished Medical Research Scientist, US Department of Veterans Affairs. He has more than 2400 publications to his credit.